Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA1257010
Max Phase: Preclinical
Molecular Formula: C26H21N3O3
Molecular Weight: 423.47
Molecule Type: Small molecule
Associated Items:
ID: ALA1257010
Max Phase: Preclinical
Molecular Formula: C26H21N3O3
Molecular Weight: 423.47
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccnc2c(NC(=O)c3ccc(N4C(=O)[C@@H]5[C@H](C4=O)[C@@H]4C=C[C@H]5C4)cc3)cccc12
Standard InChI: InChI=1S/C26H21N3O3/c1-14-11-12-27-23-19(14)3-2-4-20(23)28-24(30)15-7-9-18(10-8-15)29-25(31)21-16-5-6-17(13-16)22(21)26(29)32/h2-12,16-17,21-22H,13H2,1H3,(H,28,30)/t16-,17+,21-,22+
Standard InChI Key: BLPUCTSDPCUHQQ-NEAWWFDSSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 423.47 | Molecular Weight (Monoisotopic): 423.1583 | AlogP: 4.11 | #Rotatable Bonds: 3 |
Polar Surface Area: 79.37 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 4.18 | CX LogP: 3.47 | CX LogD: 3.47 |
Aromatic Rings: 3 | Heavy Atoms: 32 | QED Weighted: 0.51 | Np Likeness Score: -1.03 |
1. Chen B, Dodge ME, Tang W, Lu J, Ma Z, Fan CW, Wei S, Hao W, Kilgore J, Williams NS, Roth MG, Amatruda JF, Chen C, Lum L.. (2009) Small molecule-mediated disruption of Wnt-dependent signaling in tissue regeneration and cancer., 5 (2): [PMID:19125156] [10.1038/nchembio.137] |
2. Bregman H, Gunaydin H, Gu Y, Schneider S, Wilson C, DiMauro EF, Huang X.. (2013) Discovery of a class of novel tankyrase inhibitors that bind to both the nicotinamide pocket and the induced pocket., 56 (3): [PMID:23316926] [10.1021/jm301607v] |
3. Hua Z, Bregman H, Buchanan JL, Chakka N, Guzman-Perez A, Gunaydin H, Huang X, Gu Y, Berry V, Liu J, Teffera Y, Huang L, Egge B, Emkey R, Mullady EL, Schneider S, Andrews PS, Acquaviva L, Dovey J, Mishra A, Newcomb J, Saffran D, Serafino R, Strathdee CA, Turci SM, Stanton M, Wilson C, Dimauro EF.. (2013) Development of novel dual binders as potent, selective, and orally bioavailable tankyrase inhibitors., 56 (24): [PMID:24294969] [10.1021/jm401317z] |
Source(1):